Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins

NCT06711120 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-12-01
Last updated
2024-12-02

Condition(s) studied

Varicose Veins of Lower LimbVenous Insufficiency of LegVascular Disease,Peripheral

Investigational drug(s) / intervention(s)

Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively

Radiofrequency ablation and microwave ablation are used to treat small saphenous varicose veins, respectively: During the procedure, 2% lidocaine was injected subcutaneously along the course of the saphenous vein under ultrasound guidance, and after local anaesthesia, an incision was made at the ankle joint of the saphenous vein to locate the saphenous vein, and a radiofrequency guidewire and catheter sheath were introduced.The saphenous vein was incised at the ankle joint under local anaesthesia. Under ultrasound monitoring, the radiofrequency catheter was placed in the saphenous popliteal vein at a distance of 1\~2 cm and the position of the catheter was fixed, and then anaesthesia and swelling fluid was injected into the fascial tissues around the main trunk of the small saphenous vein in segments.The two groups were treated with radiofrequency ablation and microwave ablation surgery, respectively.

Study summary

Objective: To investigate the clinical efficacy of ultrasound-guided radiofrequency ablation and microwave ablation in the treatment of primary saphenous varicose veins.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years and ≤90 years; * Clinical diagnosis of primary varicose veins of the lower extremities, CEAP clinical classification C2-C6, requiring treatment of the great and/or small saphenous vein segments, and at least 1 of the clinical symptoms of swelling, pain, burning sensation, heaviness, easy fatigue, itchy skin, and night cramps; * Valve insufficiency of the great saphenous vein, small saphenous vein, or transport vein; * Doppler ultrasound confirmation of a saphenous vein diameter greater than 3 mm and less than 12 mm in the standing position; * Only one limb per patient was selected for inclusion in the study; * Patients signed an informed consent form and were willing to co-operate in completing the protocol-specified investigations and follow-up visits. Exclusion Criteria: * Thrombosis of the great saphenous or small saphenous vein, or combined deep vein thrombosis, or previous history of deep vein thrombosis or pulmonary embolism. * Recurrent varicose veins after previous treatment. * Severe distortion of the great saphenous vein with anticipated catheter failure. * Severe lower limb ischaemia (CLI) (ABPI \<0.8). * Known allergy to medications and device materials involved in the study. * Pre-existing implanted pacemaker, defibrillator, currently on regular anticoagulation therapy (e.g., warfarin, heparin). * Women who are pregnant or breastfeeding. * Unable or unwilling to complete the questionnaire. * Participating in a study of another drug or device. * Life expectancy \<1 year. * Those undergoing treatment for skin malignancies other than non-melanoma. * Daily use of narcotic drugs or non-steroidal anti-inflammatory drugs to control pain due to venous disease. * In the judgement of the investigator, endovenous therapy is not appropriate.

Primary outcome measure(s)

  • 6-month postoperative occlusion rate — 6 months after surgery
    occlusion defined as no flow recirculation of the closed treated segment of the vein as confirmed by Doppler ultrasound

Trial sites (1)

FacilityCityRegionStatus
Hospital of Chengdu University of Traditional Chinese Medicine Chengdu China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06711120 on ClinicalTrials.gov ↗ ← All trials in China